Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Thermo Electron/Puritan-Bennett

This article was originally published in The Gray Sheet

Executive Summary

Sixty-seven percent of P-B shareholders have agreed to tender their shares for $24.50 each, Thermo announces in a Nov. 23 investor teleconference. Due to the P-B shareholder response, Thermo has extended its tender offer, scheduled to have expired Nov. 22, until midnight Nov. 28. Thermo's Chief Financial Officer John Hatsopoulos called the 67.3% response "a wonderful vote of confidence" and urged P-B's board to "listen to its shareholders." Hatsopoulos did not rule out a proxy battle but indicated that Thermo has no plans to attempt to overturn anti-takeover measures through litigation. Thermo initiated its $24.50 offer on Oct. 25. After P-B's board determined that the offer was inadequate, Hatsopoulos maintained that it was his firm's "best offer" in a Nov. 9 teleconference ("The Gray Sheet" Nov. 14, I&W-6). In that story, "The Gray Sheet" incorrectly identified John Hatsopoulos as his brother, company President and Chairman George Hatsopoulos

Latest Headlines
See All
UsernamePublicRestriction

Register

MT003133

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel